Trials / Withdrawn
WithdrawnNCT03891849
Macro and Microcirculatory Effects of the Combination of Norepinephrine and Octreotide for the Treatment of Cirrhotic Patients With Hemorrhagic Shock
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Centre Hospitalier Universitaire, Amiens · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Octreotide is used to decrease portal pressure of cirrhotic patients admitted for variceal bleeding. When patients are in haemorrhagic shock, the recommended drug to increase arterial pressure is norepinephrine. Microcirculatory effects of octreotide when it is added to noradrenaline has not been investigated yet. The aim of the study is to evaluate the effect of octreotide plus norepinephrine for patient with haemorrhagic shock after variceal bleeding.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Octreotide Injection | Patients admitted in intensive care unit after variceal hemorrhage treated with norepinephrine perfusion will received an additional octreotide perfusion during one hour. |
Timeline
- Start date
- 2021-09-01
- Primary completion
- 2023-05-01
- Completion
- 2023-05-01
- First posted
- 2019-03-27
- Last updated
- 2023-02-09
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03891849. Inclusion in this directory is not an endorsement.